查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症疫苗市場規模、佔有率、趨勢分析報告：按適應症類型、疫苗類型、技術類型、地區和細分市場趨勢：2023-2030
市場調查報告書
商品編碼
1321366

癌症疫苗市場規模、佔有率、趨勢分析報告：按適應症類型、疫苗類型、技術類型、地區和細分市場趨勢：2023-2030

Cancer Vaccine Market Size, Share & Trends Analysis Report By Indication Type (Bladder, Cervical), By Vaccine Type (Preventive, Therapeutic), By Technology Type (Recombinant, Whole-cell), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

癌症疫苗市場成長與趨勢

Grand View Research, Inc.最新報告顯示，預計2023年至2030年全球癌症疫苗市場規模將以11.04%的年複合成長率成長，2030年將達到168.4億美元。

人口中癌症盛行率的增加推動了市場的成長。根據世界衛生組織統計，癌症是全球頭號死亡原因，2020年將有1000萬人死亡，其中前列腺癌、肺癌、乳腺癌、結腸癌、皮膚癌和胃癌最為常見。人死了。病例數的增加很大程度上是由於多種要素造成的，包括老年人口的增加以及經濟和社會發展導致特定癌症病因盛行率的變化。這在新興經濟體尤其明顯，在這些經濟體中，與貧窮相關的癌症發生了普遍變化。這與已開發經濟體形成鮮明對比，在已開發經濟體，越來越多的病例與生活方式障礙有關。

世界衛生組織表示，肥胖、某些感染疾病和輻射暴露是導致病例增加的主要要素。此外，預防領域的技術進步顯著增加了全球對疫苗的需求。 FDA 支持生物標記和質譜流式細胞儀的開發，推出用於藥物研發和診斷的多種流式細胞術試劑，技術先進的微型化設備，有利於攜帶性和精確性，基於細胞和珠子的流式細胞儀技術的開拓是推動市場成長的主要要素。各組織為提高人們對癌症的認知而開展的各種計劃是全球創新疫苗需求不斷成長的主要要素。國家子宮頸癌聯盟、疾病預防控制中心、世界衛生組織、美國預防服務工作小組等為增加子宮頸癌篩檢而進行的合作和夥伴關係是預計在預測期內增加市場成長的關鍵因素。

此外，參與各種疫苗開發和配製的主要公司致力於聯合研究和聯盟，以開發新疫苗並保持行業競爭力。此外，多家公司致力於開發新疫苗，以滿足預防這種疾病不斷成長的需求。例如，2023年2月，BioNTech宣布計畫從2023年9月開始對其疫苗進行臨床試驗，預計疫苗將於2030年上市。2023年 3月，克利夫蘭診所的調查團隊宣布了將最致命的預防三陰性乳癌疫苗推向市場的下一步措施。

癌症疫苗市場報告亮點

  • 2022年，由於盛行率上升導致疾病預防的需要，預防性疫苗類型佔據最大的銷售佔有率。
  • 由於盛行率上升，預計子宮頸癌適應症類型在預測期內將出現最快的成長速度。
  • 從技術類型來看，由於重組技術開發的疫苗具有高可用性，重組疫苗領域將在2022年佔據全球產業的主導地位。
  • 主要企業不斷致力於產品發布和地理擴張，以保持其市場地位和佔有率。
  • 由於其發達的醫療基礎設施、高癌症盛行率、主要企業的存在以及適當的疫苗接種服務的可用性，北美將在2022年佔據最大的銷售佔有率。

目錄

第1章 癌症疫苗市場：調查方法與範圍

第2章 癌症疫苗市場：執行摘要

  • 市場簡介
  • 疫苗類型和適應症類型概況
  • 技術類型簡介
  • 競爭形勢概覽

第3章 癌症疫苗市場：產業展望

  • 市場體系預測
    • 母市場譜系預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 市場動態
    • 市場促進因素
    • 市場抑制因素分析
  • 要素因素（政治/法律、經濟/技術）進行 SWOT 分析
  • 產業分析-波特
  • 償付和法規場景
  • 主要交易和戰略聯盟
    • 新產品發布
    • 獲得
    • 擴張
    • 合夥
    • 行銷和推廣

第4章 癌症疫苗市場：競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 供應商形勢
  • 上市公司
  • 私人公司
  • 區域網路圖

第5章 癌症疫苗市場：疫苗類型商業分析

  • 定義和範圍
  • 2022年和2030年疫苗類型市佔率分析
  • 2018-2030年全球癌症疫苗市場（以疫苗類型）
  • 癌症疫苗市場：疫苗類型變異分析
  • 癌症預防疫苗
  • 治療性癌症疫苗
  • 其他

第6章 癌症疫苗市場：按適應症類型進行的業務分析

  • 定義和範圍
  • 2022年和2030年按適應症類型分類的市場佔有率分析
  • 全球癌症疫苗市場，適應症類型，2018-2030
  • 癌症疫苗市場：適應症類型波動分析
  • 攝護腺癌
  • 膀胱癌
  • 黑色素瘤
  • 子宮頸癌
  • 其他

第7章 癌症疫苗市場：技術類型的商業分析

  • 定義和範圍
  • 2022年及2030年技術類型市佔率分析
  • 2018-2030年全球癌症疫苗市場（依技術類型）
  • 癌症疫苗市場：技術類型變化分析
  • 重組癌症疫苗
  • 全細胞癌症疫苗
  • 病毒載體和 DNA 癌症疫苗
  • 其他

第8章 癌症疫苗市場：區域業務分析

  • 定義和範圍
  • 2022年及2030年區域市佔率分析
  • 區域市場儀表板
  • 區域市場簡介
  • 要素因素（政治/法律、經濟/技術）進行 SWOT 分析
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東、非洲
  • 2022年至2030年市場規模、預測、趨勢分析
  • 北美洲
    • 2018年至2030年北美疫苗市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲癌症疫苗市場，2018-2030
    • 英國
    • 德國
    • 西班牙
    • 法國
    • 義大利
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 亞太地區癌症疫苗市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
    • 澳洲
  • 拉丁美洲
    • 拉丁美洲癌症疫苗市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東、非洲
    • MEA 癌症疫苗市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 癌症疫苗市場：公司簡介

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 合夥
    • 獲得
    • 合作
    • 資金籌措
  • 2022年主要企業市佔率分析
  • 公司簡介
    • Merck & Co., Inc.
    • GSK plc
    • Dendreon Pharmaceuticals LLC.
    • Dynavax Technologies.
    • Ferring BV
    • Amgen, Inc.
    • Moderna, Inc.
    • Sanofi
    • AstraZeneca
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-096-2

Cancer Vaccine Market Growth & Trends

The global cancer vaccine market size is expected to reach USD 16.84 billion by 2030, expanding at a CAGR of 11.04% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer among the population. According to the WHO, it is a leading cause of death globally, which accounted for 10 million deaths in 2020, with prostate, lung, breast, colon, skin, and stomach cancers being the most common types causing one in every six deaths worldwide. A rise in the number of cases can be majorly attributed to various factors, such as the rising geriatric population and changing prevalence of certain causes of cancer associated with economic & social development. This is particularly seen in emerging economies, wherein a general shift is observed in terms of cancers associated with poverty, which is a contrast to developed economies, wherein cases have increasingly been associated with lifestyle disorders.

According to the WHO, obesity, certain types of infections, and exposure to radiation are major factors associated with an increase in the number of cases. Moreover, the demand for vaccines is significantly increasing worldwide owing to technological advancements in the field of prevention. FDA support for developing biomarkers & mass cytometry; launch of various flow cytometry reagents for drug discovery & diagnosis; technologically advanced miniaturized devices, facilitating portability & precision; development of cell- & bead-based flow cytometry techniques are major factors boosting the market growth. Various programs to increase awareness about cancer by organizations are key factors responsible for the increased demand for innovative vaccines worldwide. Collaborations and partnerships undertaken by the National Cervical Cancer Coalition, CDC, WHO, the U.S. Preventive Services Task Force, and others for increasing screening of cervical cancer are major factors expected to augment the market growth during the forecast period.

Furthermore, key players involved in developing and formulating various vaccines are focusing on collaborations and partnerships to develop novel vaccines and to maintain their competitive position in the industry. Moreover, several players are involved in the development of novel vaccines to meet the rising demand for prevention of the condition. For instance, in February 2023, BioNTech announced plans to proceed with clinical trials for its vaccine from September 2023, which is expected to be launched in the market before 2030. In March 2023, Researchers at Cleveland Clinic announced the next step toward the launch of a vaccine for the prevention of triple-negative breast cancer, which is one of the most lethal forms of the condition.

Cancer Vaccine Market Report Highlights

  • The preventive vaccine type segment held the largest revenue share in 2022 owing to the need for preventing the condition due to the rising prevalence
  • The cervical cancer indication type segment is expected to register the fastest growth rate over the forecast period due to the rising disease prevalence
  • On the basis of technology type, the recombinant vaccine segment dominated the global industry in 2022 due to the high availability of vaccines developed from recombinant technology
  • Key players operating are constantly focusing on product launches and geographical expansions to maintain their market position and share
  • North America held the largest revenue share in 2022 on account of the better healthcare infrastructure, the high prevalence of cancer, the presence of key players, and the availability of proper vaccination service

Table of Contents

Chapter 1 Cancer Vaccine Market: Methodology And Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Vaccine Type Segment
      • 1.1.1.2 Technology type segment
      • 1.1.1.3 Indication type segment
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List of Secondary Sources
  • 1.11 List of Abbreviations

Chapter 2 Cancer Vaccine Market: Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Vaccine Type and Indication Type Snapshot
  • 2.3 Technology Type Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Cancer Vaccine Market: Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers
      • 3.3.1.1 Increasing Prevalence of cancer
      • 3.3.1.2 Growing investments and governmental funding in the development of cancer vaccines
      • 3.3.1.3 Increasing demand for cancer vaccines
      • 3.3.1.4 Launch of new cancer vaccines
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Complex And Time-Consuming Regulatory Approval Process
      • 3.3.2.2 High Price Associated With Vaccines
  • 3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.5 Industry Analysis - Porter's
  • 3.6 Reimbursement & Regulatory Scenario
  • 3.7 Major Deals & Strategic Alliances
    • 3.7.1 New Product Launch
    • 3.7.2 Acquisition
    • 3.7.3 Expansion
    • 3.7.4 Partnerships
    • 3.7.5 Marketing & Promotions

Chapter 4 Cancer Vaccine Market: Competitive Landscape

  • 4.1 Recent developments & impact analysis, by key market participants
    • 4.1.1 Ansoff Matrix
  • 4.2 Company Categorization
    • 4.2.1 Innovators
      • 4.2.1.1 Market Differentiators
  • 4.3 Vendor Landscape
    • 4.3.1 List Of Key Distributors And Channel Partners
    • 4.3.2 Key Customers
    • 4.3.3 Key Company Market Share Analysis, 2022
  • 4.4 Public Companies
    • 4.4.1 Competitive Dashboard Analysis
  • 4.5 Private Companies
    • 4.5.1 List Of Key Emerging Companies
  • 4.6 Regional Network Map

Chapter 5 Cancer Vaccine Market: Vaccine Type Business Analysis

  • 5.1 Definition And Scope
  • 5.2 Vaccine Type Market Share Analysis, 2022 & 2030
  • 5.3 Global Cancer Vaccine Market, By Vaccine Type, 2018 To 2030
  • 5.4 Cancer Vaccine Market: Vaccine Type Movement Analysis
  • 5.5 Preventive Cancer Vaccines
    • 5.5.1 Preventive Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6 Therapeutic Cancer Vaccines
    • 5.6.1 Therapeutic Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7 Others
    • 5.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Cancer Vaccine Market: Indication Type Business Analysis

  • 6.1 Definition And Scope
  • 6.2 Indication Type Market Share Analysis, 2022 & 2030
  • 6.3 Global Cancer Vaccine Market, By Indication Type, 2018 To 2030
  • 6.4 Cancer Vaccine Market: Indication Type Movement Analysis
  • 6.5 Prostate Cancer
    • 6.5.1 Prostate Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6 Bladder Cancer
    • 6.6.1 Bladder Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7 Melanoma
    • 6.7.1 Melanoma Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8 Cervical Cancer
    • 6.8.1 Cervical Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9 Others
    • 6.9.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Cancer Vaccine Market: Technology Type Business Analysis

  • 7.1 Definition And Scope
  • 7.2 Technology Type Market Share Analysis, 2022 & 2030
  • 7.3 Global Cancer Vaccine Market, By Technology Type, 2018 To 2030
  • 7.4 Cancer Vaccine Market: Technology Type Movement Analysis
  • 7.5 Recombinant Cancer Vaccines
    • 7.5.1 Recombinant Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.6 Whole-Cell Cancer Vaccines
    • 7.6.1 Whole-Cell Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.7 Viral Vector And Dna Cancer Vaccines
    • 7.7.1 Viral Vector And Dna Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.8 Others
    • 7.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Cancer Vaccine Market: Regional Business Analysis

  • 8.1 Definition & Scope
  • 8.2 Regional Market Share Analysis, 2022 & 2030
  • 8.3 Regional Market Dashboard
  • 8.4 Regional Market Snapshot
  • 8.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
    • 8.5.1 North America
    • 8.5.2 Europe
    • 8.5.3 Asia Pacific
    • 8.5.4 Latin America
    • 8.5.5 Mea
  • 8.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
  • 8.7 North America
    • 8.7.1 North America Cancer Vaccine Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.7.2 U.S.
      • 8.7.2.1 U.S. Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.7.2.2 Key Country Dynamics
      • 8.7.2.3 Regulatory Framework
      • 8.7.2.4 Competitive Scenario
    • 8.7.3 Canada
      • 8.7.3.1 Canada Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.7.3.2 Key Country Dynamics
      • 8.7.3.3 Regulatory Framework
      • 8.7.3.4 Competitive Scenario
  • 8.8 Europe
    • 8.8.1 Europe Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.8.2 UK
      • 8.8.2.1 UK Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.2.2 Key Country Dynamics
      • 8.8.2.3 Regulatory Framework
      • 8.8.2.4 Competitive Scenario
    • 8.8.3 Germany
      • 8.8.3.1 Germany Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.3.2 Key Country Dynamics
      • 8.8.3.3 Regulatory Framework
      • 8.8.3.4 Competitive Scenario
    • 8.8.4 Spain
      • 8.8.4.1 Spain Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.4.2 Key Country Dynamics
      • 8.8.4.3 Regulatory Framework
      • 8.8.4.4 Competitive Scenario
    • 8.8.5 France
      • 8.8.5.1 France Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.5.2 Key Country Dynamics
      • 8.8.5.3 Regulatory Framework
      • 8.8.5.4 Competitive Scenario
    • 8.8.6 Italy
      • 8.8.6.1 Italy Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.6.2 Key Country Dynamics
      • 8.8.6.3 Regulatory Framework
      • 8.8.6.4 Competitive Scenario
    • 8.8.7 Norway
      • 8.8.7.1 Norway Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.7.3 Regulatory Framework
      • 8.8.7.4 Competitive Scenario
    • 8.8.8 Denmark
      • 8.8.8.1 Denmark Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.8.2 Key Country Dynamics
      • 8.8.8.3 Regulatory Framework
      • 8.8.8.4 Competitive Scenario
    • 8.8.9 Sweden
      • 8.8.9.1 Sweden Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.9.2 Key Country Dynamics
      • 8.8.9.3 Regulatory Framework
      • 8.8.9.4 Competitive Scenario
  • 8.9 Asia Pacific
    • 8.9.1 Asia-Pacific Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.9.2 Japan
      • 8.9.2.1 Japan Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.2.2 Key Country Dynamics
      • 8.9.2.3 Regulatory Framework
      • 8.9.2.4 Competitive Scenario
    • 8.9.3 China
      • 8.9.3.1 China Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.3.2 Key Country Dynamics
      • 8.9.3.3 Regulatory Framework
      • 8.9.3.4 Competitive Scenario
    • 8.9.4 India
      • 8.9.4.1 India Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.4.2 Key Country Dynamics
      • 8.9.4.3 Regulatory Framework
      • 8.9.4.4 Competitive Scenario
    • 8.9.5 South Korea
      • 8.9.5.1 South Korea Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.5.2 Key Country Dynamics
      • 8.9.5.3 Regulatory Framework
      • 8.9.5.4 Competitive Scenario
    • 8.9.6 Thailand
      • 8.9.6.1 Thailand Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.6.2 Key Country Dynamics
      • 8.9.6.3 Regulatory Framework
      • 8.9.6.4 Competitive Scenario
    • 8.9.7 Australia
      • 8.9.7.1 Australia Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.7.2 Key Country Dynamics
      • 8.9.7.3 Regulatory Framework
      • 8.9.7.4 Competitive Scenario
  • 8.10 Latin America
    • 8.10.1 Latin America Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.10.2 Brazil
      • 8.10.2.1 Brazil Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.2.2 Key Country Dynamics
      • 8.10.2.3 Regulatory Framework
      • 8.10.2.4 Competitive Scenario
    • 8.10.3 Mexico
      • 8.10.3.1 Mexico Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.3.2 Key Country Dynamics
      • 8.10.3.3 Regulatory Framework
      • 8.10.3.4 Competitive Scenario
    • 8.10.4 Argentina
      • 8.10.4.1 Argentina Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.4.2 Key Country Dynamics
      • 8.10.4.3 Regulatory Framework
      • 8.10.4.4 Competitive Scenario
  • 8.11 MEA
    • 8.11.1 MEA Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.11.2 South Africa
      • 8.11.2.1 South Africa Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.2.2 Key Country Dynamics
      • 8.11.2.3 Regulatory Framework
      • 8.11.2.4 Competitive Scenario
    • 8.11.3 Saudi Arabia
      • 8.11.3.1 Saudi Arabia Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.3.2 Key Country Dynamics
      • 8.11.3.3 Regulatory Framework
      • 8.11.3.4 Competitive Scenario
    • 8.11.4 UAE
      • 8.11.4.1 UAE Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.4.2 Key Country Dynamics
      • 8.11.4.3 Regulatory Framework
      • 8.11.4.4 Competitive Scenario
    • 8.11.5 Kuwait
      • 8.11.5.1 Kuwait Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.5.2 Key Country Dynamics
      • 8.11.5.3 Regulatory Framework
      • 8.11.5.4 Competitive Scenario

Chapter 9 Cancer Vaccine Market: Company Profiling

  • 9.1 Company Categorization
  • 9.2 Strategy Mapping
    • 9.2.1 New Product Launch
    • 9.2.2 Partnerships
    • 9.2.3 Acquisition
    • 9.2.4 Collaboration
    • 9.2.5 Funding
  • 9.3 Key Company Market Share Analysis, 2022
  • 9.4 Company Profiles
    • 9.4.1 Merck & Co., Inc.
      • 9.4.1.1 Company Overview
      • 9.4.1.2 Financial Performance
      • 9.4.1.3 Product Benchmarking
      • 9.4.1.4 Strategic Initiatives
    • 9.4.2 GSK plc
      • 9.4.2.1 Company Overview
      • 9.4.2.2 Financial Performance
      • 9.4.2.3 Product Benchmarking
      • 9.4.2.4 Strategic Initiatives
    • 9.4.3 Dendreon Pharmaceuticals LLC.
      • 9.4.3.1 Company Overview
      • 9.4.3.2 Product Benchmarking
      • 9.4.3.3 Strategic Initiatives
    • 9.4.4 Dynavax Technologies.
      • 9.4.4.1 Company Overview
      • 9.4.4.2 Financial Performance
      • 9.4.4.3 Product Benchmarking
      • 9.4.4.4 Strategic Initiatives
    • 9.4.5 Ferring B.V.
      • 9.4.5.1 Company Overview
      • 9.4.5.2 Financial Performance
      • 9.4.5.3 Product Benchmarking
      • 9.4.5.4 Strategic Initiatives
    • 9.4.6 Amgen, Inc.
      • 9.4.6.1 Company Overview
      • 9.4.6.2 Financial Performance
      • 9.4.6.3 Product Benchmarking
      • 9.4.6.4 Strategic Initiatives
    • 9.4.7 Moderna, Inc.
      • 9.4.7.1 Company Overview
      • 9.4.7.2 Financial Performance
      • 9.4.7.3 Product Benchmarking
      • 9.4.7.4 Strategic Initiatives
    • 9.4.8 Sanofi
      • 9.4.8.1 Company Overview
      • 9.4.8.2 Financial Performance
      • 9.4.8.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives
    • 9.4.9 AstraZeneca
      • 9.4.9.1 Company Overview
      • 9.4.9.2 Financial Performance
      • 9.4.9.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives
    • 9.4.10 Bristol-Myers Squibb Company
      • 9.4.9.1 Company Overview
      • 9.4.9.2 Financial Performance
      • 9.4.9.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Cancer Vaccine Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 5 Global Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 6 Global Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 7 North America Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 9 North America Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 10 North America Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 21 UK Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 22 UK Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 23 UK Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 27 France Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 28 France Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 29 France Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 31 Italy Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 32 Italy Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 35 Spain Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 37 Denmark Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 40 Sweden Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 43 Norway Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 44 Norway Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 50 Japan Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 51 Japan Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 52 China Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 53 China Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 54 China Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 55 India Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 56 India Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 57 India Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 59 South Korea Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 62 Australia Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 65 Thailand Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 68 Latin America Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 69 Latin America Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 72 Brazil Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 75 Mexico Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 88 South Africa Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Cancer Vaccine Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Cancer vaccine market: Vaccine Type outlook and key takeaways
  • Fig. 15 Cancer vaccine market: Vaccine Type movement analysis & market share 2022 & 2030
  • Fig. 16 Preventive cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 17 Therapeutic cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 Cancer vaccine market: Indication type outlook and key takeaways
  • Fig. 20 Cancer vaccine market: Indication type movement analysis & market share 2022 & 2030
  • Fig. 21 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Bladder cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Melanoma market, 2018 - 2030 (USD Million)
  • Fig. 24 Cervical cancer market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 Cancer vaccine market: Technology type outlook and key takeaways
  • Fig. 27 Cancer vaccine market: Technology type movement analysis & market share 2022 & 2030
  • Fig. 28 Recombinant cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 29 Whole-cell cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 30 Viral vector and DNA cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 31 Other technologies market, 2018 - 2030 (USD Million)
  • Fig. 32 Regional Marketplace: Key Takeaways
  • Fig. 33 Regional Outlook, 2022 & 2030
  • Fig. 34 Regional Market Dashboard
  • Fig. 35 Regional Market Place: Key Takeaways
  • Fig. 36 North America, SWOT Analysis
  • Fig. 37 Europe, SWOT Analysis
  • Fig. 38 Asia Pacific, SWOT Analysis
  • Fig. 39 Latin America, SWOT Analysis
  • Fig. 40 MEA, SWOT Analysis
  • Fig. 41 North America
  • Fig. 42 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Key Country Dynamics
  • Fig. 44 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Canada Key Country Dynamics
  • Fig. 46 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Europe
  • Fig. 48 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 49 UK Key Country Dynamics
  • Fig. 50 UK Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Germany Key Country Dynamics
  • Fig. 52 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 53 France Key Country Dynamics
  • Fig. 54 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Italy Key Country Dynamics
  • Fig. 56 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Spain Key Country Dynamics
  • Fig. 58 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark Key Country Dynamics
  • Fig. 60 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden Key Country Dynamics
  • Fig. 62 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Norway Key Country Dynamics
  • Fig. 64 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific
  • Fig. 66 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Japan Key Country Dynamics
  • Fig. 68 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 69 China Key Country Dynamics
  • Fig. 70 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 71 India Key Country Dynamics
  • Fig. 72 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Australia Key Country Dynamics
  • Fig. 74 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Thailand Key Country Dynamics
  • Fig. 76 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 77 South Korea Key Country Dynamics
  • Fig. 78 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America
  • Fig. 80 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil Key Country Dynamics
  • Fig. 82 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Mexico Key Country Dynamics
  • Fig. 84 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina Key Country Dynamics
  • Fig. 86 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 87 MEA
  • Fig. 88 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa Key Country Dynamics
  • Fig. 90 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 91 Saudi Arabia Key Country Dynamics
  • Fig. 92 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 93 UAE Key Country Dynamics
  • Fig. 94 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 95 Kuwait Key Country Dynamics
  • Fig. 96 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 97 Strategy Mapping